Canon Medical Offers New Liver Reporting Tool for Ultrasound

December 1, 2020

Canon Medical reminds us that liver disease is one of the major challenges in imaging today, and accurately determining compensated advanced chronic liver disease (cACLD) is extremely important in order to define the right treatment path.

The recently updated guidelines from Society of Radiologists in Ultrasound introduced the “Rule of Four,” a standardized method of using four different levels of shear wave elastography-based liver stiffness to assess the probability of cACLD. To help easily and accurately determine cut off values, Canon Medical Systems USA, Inc.’s premium AplioTM i-series ultrasound platform is now available with software to display the calculated measurement averages from multiple samples of the liver, customizable based on the “Rule of Four.”

The program uses measurements obtained with Shear Wave Elastography, Canon Medical’s technology that provides a quantitative measure and dynamic visual display of tissue stiffness in the liver. In addition, the system provides standard deviation and interquartile range (IQR) data, as well as a simple visual propagation map, to ensure accurate and confident application of the “Rule of Four” to determine cACLD and for the assessment of other liver pathologies.

“The new guidelines from SRU reinforce the importance of quickly and accurately determining cACLD, so that clinicians can chart the right course for patient care,” said Dan Skyba, managing director, Ultrasound Business Unit, Canon Medical Systems USA, Inc. “At Canon Medical, it doesn’t get much easier than automatically calculating that average measurement of tissue stiffness, with our Shear Wave Elastography plus this new liver reporting tool.”

The Aplio i-series will be showcased at this year’s virtual Radiological Society of North America (RSNA), at Canon Medical’s unique, immersive booth experience.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.